Issue 8 / Week of 21-27 July 2026

Lilly is recruiting depression patients in Germany, Greece, Poland and Spain right now. Nine days before that trial's latest update, the same company agreed to pay up to $3.8 billion for two psychedelics and did not write a single European milestone into the deal.

The trial is RENEW-MDD 1 (NCT07412756), testing brenipatide in major depressive disorder. An adjunctive relapse-prevention study, drug versus placebo, recruiting across fifteen countries, four of them EU member states. Relapse prevention is not an exploratory design. It is what a company runs when it expects to sell something.

Set that against the deal we covered last week. Lilly's contingent value right pays $1.00 a share on the initiation of a Phase 3 for VLS-01, with no geography named. It pays $0.50 on US approval and DEA rescheduling of BPL-003, and $1.00 on US approval and DEA rescheduling of VLS-01. Every dollar tied to an approval is tied to an American one.

We want to be careful here, because the obvious version of this story is not quite the true one. We checked whether Lilly routinely builds European sites for late-stage brain and mood programmes. It does so about half the time. Of its current late-stage CNS trials, some carry EU-member sites, and several recent Alzheimer's pivotals carry none at all. Brenipatide is also the company's only active Phase 3 in psychiatry, so there is no peer group against which to call it typical or unusual. Anyone who tells you Lilly always builds in Europe has not looked.

That complication is more interesting than the simple story would have been. It suggests the psychedelic case is not an exception to how Lilly treats Europe. It may be the sharpest instance of a broader recalculation about what European late-stage development is worth. When the asset is a conventional molecule in a large indication, Europe still earns sites. When the asset is expensive, uncertain, or hard to deliver, Europe increasingly does not.

That is the thesis worth holding, and it is bigger than psychedelics.

The reflexive explanation is that Europe will not fund supervised psychiatric treatment. That explanation is wrong, and the evidence is sitting in plain view.

Esketamine is a clinic-administered psychiatric drug that requires monitored dosing. Germany reimburses it. In September 2023 the G-BA found an indication of considerable additional benefit for treatment-resistant depression in combination with an SSRI or SNRI, upgrading an earlier finding that the benefit was not proven. The Netherlands reimburses it too, from the basic insurance package since September 2021, restricted to the fourth step of the treatment algorithm and priced under a negotiated arrangement. Britain is the outlier. NICE did not recommend it, citing clinical and cost-effectiveness uncertainty and the cost of running esketamine clinics.

So the question is not whether Europe pays for supervised psychiatry. Two of its largest health systems already do.

The question is what makes a psychedelic different, and there are two answers.

The first is cost. In Switzerland, where psychedelic-assisted therapy is legally available, the full cost of a single treatment day is estimated at CHF 3,000 to 4,000, with patients typically charged between CHF 800 and 2,000. The substance itself accounts for CHF 100 to 450 of that. A British modelling study put the expected healthcare cost of psilocybin-assisted therapy at £6,132 to £7,652 per person. Almost none of that is the drug. It is the hours.

The second is that nobody has walked through the door. Germany reimburses esketamine because a manufacturer took it through a formal benefit assessment and demonstrated added value against a defined comparator. That assessment is the gate. No psilocybin or MDMA therapy has been through it, in Germany or anywhere else in Europe. Access is not the same as assessment, and assessment is what unlocks payment.

Switzerland has the patients and none of the payment. Under the limited medical use exception in Swiss narcotics law, operating since 2014 and extended to psilocybin in 2021, around 100 physicians held authorisations to treat 723 patients in 2024, roughly 1,660 treatments in total. That is the largest legal psychedelic treatment programme in Europe by some distance. Every patient pays out of pocket. Mandatory health insurance does not cover it.

We read that as demand evidence that will eventually pressure payers, and we hold the obvious caveat alongside it. The programme has run for over a decade, and reimbursement has not followed. Demand alone has proven insufficient. Something has to force the assessment.

Germany has quietly opened the door that the others have not. The BfArM has approved a compassionate use programme for psilocybin in treatment-resistant depression, running at the Central Institute of Mental Health in Mannheim and a Berlin day clinic, using botanical psilocybin supplied by Filament Health. It is the first of its kind in the European Union. We have carried this as unconfirmed since Issue 3, and it is now sourced. What we still cannot confirm is who bears the cost of delivery, and that omission is not trivial. A compassionate use programme establishes that a regulator will permit the treatment. It does not establish that a payer will fund it.

Zero. Newly registered interventional psychedelic trials with a site in the EU, EEA, UK or Switzerland during the week of 21 to 27 July. Four studies matched our search terms and dates. All four were excluded: one observational, one in Taiwan, two in the United States with no European site.

This is the second consecutive week at zero. One week is noise. Two is worth writing down.

EU / EMA. The division of labour has not changed and it is the whole problem. A centralised approval is valid across every member state on the day it lands. The EMA states plainly that it has no role in decisions on pricing and reimbursement, which happen at national and regional level. The Joint Clinical Assessment framework, applicable since January 2025, harmonises the clinical review across member states and leaves the money decision exactly where it was.

Germany. The statutory health insurance cost-containment law passed the Bundestag on 10 July, raising the static manufacturer discount to 15.5 percent. Worth being precise about what this does and does not do. It squeezes manufacturer margins on drugs sold to statutory insurance. It does not change the benefit assessment process that determines whether a new therapy gets reimbursed at all. The gate is unchanged. The prize behind it is smaller.

Controlled substance status. Drug scheduling in the European Union is a national competence. Member states legislate independently and the instruments the EU uses in this area are not binding, which is why classification differs across the bloc. The clearest published work on this examines novel psychoactive substances rather than classical psychedelics, so we state the general structure and not a psychedelic-specific claim. The general structure is enough to make the point. A scheduled medicine faces twenty-seven separate legal regimes on top of twenty-seven separate payers.

Scoring the open calls. Five calls are live, and none has resolved. Issue 3, that AtaiBeckley reports a first BPL-003 Phase 3 patient dosed in Q3 2026, resolves 30 September and remains open, though the registry still shows no Phase 3 to dose into. Issue 4, that Definium's Panorama posts a smaller placebo-adjusted effect than Voyage, waits on both toplines and is open. Issue 5, that BPL-003's Phase 3 registers as adjunctive with no SSRI washout, waits on the protocol and is open. Issue 6, that COMP360 is not commercially prescribable in the United States by 30 June 2027, is open. Issue 7, that neither BPL-003 nor VLS-01 registers a Phase 3 with an EU-member-state site and that Lilly discloses no EMA pathway within twelve months of the deal closing, is open and not falsified. We checked every prong this week. No Phase 3 exists for either drug anywhere; the only EU-member sites remain in a completed Phase 2b, and no European pathway has been disclosed.

One honest note on that call. We learned things this week that cut both ways. Germany is more receptive than we assumed when we made it, with esketamine reimbursed and the first compassionate use programme in the union. Against that, no psychedelic is anywhere near the benefit assessment that unlocks payment. Our confidence is unchanged, and we would rather say that than pretend new evidence only ever confirms us.

This week's call. No psilocybin or MDMA therapy will enter a formal health technology assessment or benefit assessment process in Germany, the Netherlands or the United Kingdom before 31 December 2027. This is our read and not anyone's stated plan. The reasoning is in the Context section. Assessment requires a filing, filing requires an approval, and no classical psychedelic is close to one in Europe. If a manufacturer submits a psilocybin or MDMA therapy to the G-BA, Zorginstituut Nederland, or NICE before that date, we are wrong.

Resolve: 31 December 2027.

If something here is factually wrong, please tell me, and I will correct it openly.

Thank you so much for reading.

Dhruv Shekhawat